{"id":745214,"date":"2015-04-21T07:30:00","date_gmt":"2015-04-21T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/"},"modified":"2025-11-07T01:25:15","modified_gmt":"2025-11-07T06:25:15","slug":"merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/","title":{"rendered":"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today reaffirmed its longstanding commitment to discovering and<br \/>\n      developing novel medicines in the global fight against infectious<br \/>\n      diseases, including infections caused by resistant bacteria and other<br \/>\n      pathogens. At this year\u2019s 25th European Congress of Clinical<br \/>\n      Microbiology and Infectious Diseases (ECCMID), April 25-28 in<br \/>\n      Copenhagen, Denmark, researchers are scheduled to present more than 30<br \/>\n      scientific data presentations on the company\u2019s broad portfolio of<br \/>\n      marketed and investigational anti-infective medicines.\n    <\/p>\n<p>\n      \u201cThe rise in infections that are resistant to current antibiotics has<br \/>\n      become one of the world\u2019s most pressing public health problems,\u201d said<br \/>\n      Dr. Julie Gerberding, executive vice president, strategic<br \/>\n      communications, global public policy and population health, Merck. \u201cWe<br \/>\n      at Merck are proud to reaffirm our long-standing commitment to develop<br \/>\n      new therapeutics to fight infectious diseases, and to continue to<br \/>\n      collaborate with others to support antimicrobial stewardship to help<br \/>\n      slow the rate of emerging resistance.\u201d\n    <\/p>\n<p>\n      Merck completed its acquisition of Cubist Pharmaceuticals, Inc. on Jan.<br \/>\n      21, 2015, and continues to build on both companies\u2019 work in infectious<br \/>\n      disease. Antimicrobial research remains an important area of focus. In<br \/>\n      addition to a combined portfolio of antibiotic and antifungal medicines,<br \/>\n      vaccines, and medicines for HIV and HCV, Merck has multiple programs<br \/>\n      that span discovery through late-stage development. In total, Merck<br \/>\n      currently has more than 15 ongoing clinical trials evaluating<br \/>\n      antibiotic, antifungal and antiviral agents for the prevention and<br \/>\n      treatment of infectious disease. These trials are projected to enroll<br \/>\n      approximately 8,000 patients.\n    <\/p>\n<p>\n      Continued innovation in developing new anti-infective medicines is<br \/>\n      critical to address growing unmet medical needs and mitigate the growing<br \/>\n      problem of antibiotic and antifungal resistance. In addition to in-house<br \/>\n      anti-infective research efforts, Merck augments its expertise and<br \/>\n      resources by collaborating with scientists across the world. The company<br \/>\n      is committed to working with partners to help address this unmet need<br \/>\n      and recognizes that new methods and a broader scope of partnering \u2013 with<br \/>\n      both public and private entities \u2013 are essential to harnessing<br \/>\n      innovation.\n    <\/p>\n<p>\n      Merck has a long history of collaborating with others in infectious<br \/>\n      diseases and the company was the first to mass produce penicillin for<br \/>\n      the war effort in the 1940s. More recently, since 2002, Merck has<br \/>\n      sponsored the Study for Monitoring Antimicrobial Resistance Trends<br \/>\n      (SMART). SMART monitors the <i>in vitro<\/i> susceptibility of clinical<br \/>\n      bacterial isolates to selected antimicrobials in the United States and<br \/>\n      internationally. The information collected and shared is designed to<br \/>\n      help local and global health agencies improve surveillance to better<br \/>\n      understand trends in antimicrobial resistance and select appropriate<br \/>\n      antibiotics for patients.\n    <\/p>\n<p>\n      In the last five years, Merck researchers have published more than 30<br \/>\n      peer-reviewed research articles in this disease area. The company also<br \/>\n      provides access for researchers to publish small molecule chemical<br \/>\n      probes, genetic tools, as well as recent clinical isolates and<br \/>\n      genetically engineered libraries of disease-relevant bacterial and<br \/>\n      fungal strains developed in our laboratories.\n    <\/p>\n<p>\n      As a leader in infectious diseases, Merck is committed to:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Maintain active R&amp;D programs to address unmet medical needs in the<br \/>\n        prevention and treatment of infectious disease.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Monitor antibacterial resistance emergence in collaboration with<br \/>\n        external partners, as exemplified by our longstanding commitment to<br \/>\n        surveillance studies.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Support responsible use of antimicrobials to help slow development of<br \/>\n        resistance and preserve current therapeutic options.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Advocate for improvements in regulatory guidance and financial<br \/>\n        incentives to support and accelerate innovation in the development of<br \/>\n        new antimicrobials, vaccines, services and solutions.\n      <\/li>\n<\/ul>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51083064&amp;newsitemid=20150421005125&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=402c5cd9abc4bb068a30ae2ac1b64589\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51083064&amp;newsitemid=20150421005125&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=40c9e442f82fe63a8b395bf0ba315505\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51083064&amp;newsitemid=20150421005125&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=461873bcd260438ba3064489401c58a7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51083064&amp;newsitemid=20150421005125&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=a13bc559b68c58d4300e34beabf0ebcf\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51083064&amp;newsitemid=20150421005125&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=b9bd45e4f4721dd6c24880ced38e8d7f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Robert        Consalvo, 908-295-0928<br \/>or<br \/>Investors:<br \/>Joe Romanelli,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year\u2019s 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company\u2019s broad portfolio of marketed and investigational anti-infective medicines. \u201cThe rise in infections that are resistant to current antibiotics has become one of the world\u2019s most pressing public health problems,\u201d said Dr. Julie Gerberding, executive vice president, strategic communications, global public policy and population health, Merck. \u201cWe at Merck are proud to reaffirm our long-standing commitment to develop new therapeutics to fight infectious diseases, and to continue to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745214","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year\u2019s 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company\u2019s broad portfolio of marketed and investigational anti-infective medicines. \u201cThe rise in infections that are resistant to current antibiotics has become one of the world\u2019s most pressing public health problems,\u201d said Dr. Julie Gerberding, executive vice president, strategic communications, global public policy and population health, Merck. \u201cWe at Merck are proud to reaffirm our long-standing commitment to develop new therapeutics to fight infectious diseases, and to continue to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:15+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/\",\"name\":\"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-04-21T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/","og_locale":"en_US","og_type":"article","og_title":"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year\u2019s 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company\u2019s broad portfolio of marketed and investigational anti-infective medicines. \u201cThe rise in infections that are resistant to current antibiotics has become one of the world\u2019s most pressing public health problems,\u201d said Dr. Julie Gerberding, executive vice president, strategic communications, global public policy and population health, Merck. \u201cWe at Merck are proud to reaffirm our long-standing commitment to develop new therapeutics to fight infectious diseases, and to continue to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:15+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/","name":"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-04-21T07:30:00+00:00","dateModified":"2025-11-07T06:25:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150421005125r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-continued-commitment-to-developing-innovative-medicines-for-the-treatment-of-infectious-diseases-at-25th-annual-eccmid-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9d962964-f38c-4817-8e3d-0d8ee829f972","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745214\/revisions"}],"predecessor-version":[{"id":3674653,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745214\/revisions\/3674653"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745214"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}